vs
MESA LABORATORIES INC（MLAB）与PagerDuty, Inc.（PD）财务数据对比。点击上方公司名可切换其他公司
PagerDuty, Inc.的季度营收约是MESA LABORATORIES INC的1.9倍（$124.5M vs $65.1M），PagerDuty, Inc.净利率更高（129.7% vs 5.6%，领先124.2%），PagerDuty, Inc.同比增速更快（4.7% vs 3.6%），PagerDuty, Inc.自由现金流更多（$24.1M vs $18.0M），过去两年PagerDuty, Inc.的营收复合增速更高（5.9% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
PagerDuty是一家美国云计算企业，主打面向IT运维部门的SaaS事件管理平台，可帮助企业实时响应运维异常、快速定位并处理故障，保障业务系统稳定运行，目前已成为全球IT运维领域广受认可的数字化解决方案服务商。
MLAB vs PD — 直观对比
营收规模更大
PD
是对方的1.9倍
$65.1M
营收增速更快
PD
高出1.1%
3.6%
净利率更高
PD
高出124.2%
5.6%
自由现金流更多
PD
多$6.0M
$18.0M
两年增速更快
PD
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $124.5M |
| 净利润 | $3.6M | $161.6M |
| 毛利率 | 64.2% | 85.3% |
| 营业利润率 | 12.2% | 6.5% |
| 净利率 | 5.6% | 129.7% |
| 营收同比 | 3.6% | 4.7% |
| 净利润同比 | 316.6% | 2827.7% |
| 每股收益（稀释后） | $0.65 | $1.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABPD
| Q4 25 | $65.1M | $124.5M | ||
| Q3 25 | $60.7M | $123.4M | ||
| Q2 25 | $59.5M | $119.8M | ||
| Q1 25 | $62.1M | $121.4M | ||
| Q4 24 | $62.8M | $118.9M | ||
| Q3 24 | $57.8M | $115.9M | ||
| Q2 24 | $58.2M | $111.2M | ||
| Q1 24 | $58.9M | $111.1M |
净利润MLABPD
| Q4 25 | $3.6M | $161.6M | ||
| Q3 25 | $2.5M | $9.6M | ||
| Q2 25 | $4.7M | $-7.2M | ||
| Q1 25 | $-7.1M | $-8.8M | ||
| Q4 24 | $-1.7M | $-5.9M | ||
| Q3 24 | $3.4M | $-10.9M | ||
| Q2 24 | $3.4M | $-17.1M | ||
| Q1 24 | $-254.6M | $-28.2M |
毛利率MLABPD
| Q4 25 | 64.2% | 85.3% | ||
| Q3 25 | 61.5% | 84.6% | ||
| Q2 25 | 62.0% | 84.0% | ||
| Q1 25 | 61.8% | 83.6% | ||
| Q4 24 | 63.3% | 83.0% | ||
| Q3 24 | 61.3% | 82.7% | ||
| Q2 24 | 64.0% | 82.6% | ||
| Q1 24 | 62.1% | 81.7% |
营业利润率MLABPD
| Q4 25 | 12.2% | 6.5% | ||
| Q3 25 | 7.8% | 2.9% | ||
| Q2 25 | 5.1% | -8.6% | ||
| Q1 25 | 2.4% | -9.6% | ||
| Q4 24 | 9.2% | -8.7% | ||
| Q3 24 | 6.1% | -13.8% | ||
| Q2 24 | 9.6% | -19.5% | ||
| Q1 24 | -460.6% | -30.1% |
净利率MLABPD
| Q4 25 | 5.6% | 129.7% | ||
| Q3 25 | 4.1% | 7.8% | ||
| Q2 25 | 8.0% | -6.0% | ||
| Q1 25 | -11.4% | -7.2% | ||
| Q4 24 | -2.7% | -5.0% | ||
| Q3 24 | 5.9% | -9.4% | ||
| Q2 24 | 5.8% | -15.4% | ||
| Q1 24 | -432.2% | -25.3% |
每股收益（稀释后）MLABPD
| Q4 25 | $0.65 | $1.69 | ||
| Q3 25 | $0.45 | $0.10 | ||
| Q2 25 | $0.85 | $-0.07 | ||
| Q1 25 | $-1.30 | $-0.12 | ||
| Q4 24 | $-0.31 | $-0.07 | ||
| Q3 24 | $0.63 | $-0.14 | ||
| Q2 24 | $0.62 | $-0.26 | ||
| Q1 24 | $-47.26 | $-0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $547.8M |
| 总债务越低越好 | $68.4M | — |
| 股东权益账面价值 | $186.7M | $320.5M |
| 总资产 | $434.8M | $1.0B |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MLABPD
| Q4 25 | $29.0M | $547.8M | ||
| Q3 25 | $20.4M | $567.9M | ||
| Q2 25 | $21.3M | $597.1M | ||
| Q1 25 | $27.3M | $570.8M | ||
| Q4 24 | $27.3M | $542.2M | ||
| Q3 24 | $24.3M | $599.3M | ||
| Q2 24 | $28.5M | $592.8M | ||
| Q1 24 | $28.2M | $571.2M |
总债务MLABPD
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | $484.5M | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | $489.5M |
股东权益MLABPD
| Q4 25 | $186.7M | $320.5M | ||
| Q3 25 | $178.5M | $180.7M | ||
| Q2 25 | $172.5M | $145.7M | ||
| Q1 25 | $159.8M | $129.8M | ||
| Q4 24 | $155.2M | $111.6M | ||
| Q3 24 | $161.5M | $164.7M | ||
| Q2 24 | $150.7M | $174.0M | ||
| Q1 24 | $145.4M | $171.6M |
总资产MLABPD
| Q4 25 | $434.8M | $1.0B | ||
| Q3 25 | $430.4M | $891.5M | ||
| Q2 25 | $435.7M | $926.8M | ||
| Q1 25 | $433.3M | $927.3M | ||
| Q4 24 | $433.3M | $866.8M | ||
| Q3 24 | $454.1M | $916.0M | ||
| Q2 24 | $440.4M | $924.0M | ||
| Q1 24 | $446.8M | $925.3M |
负债/权益比MLABPD
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | 3.73× | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | 2.85× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $24.8M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $24.1M |
| 自由现金流率自由现金流/营收 | 27.7% | 19.3% |
| 资本支出强度资本支出/营收 | 1.1% | 0.6% |
| 现金转化率经营现金流/净利润 | 5.17× | 0.15× |
| 过去12个月自由现金流最近4个季度 | $37.9M | $117.6M |
8季度趋势，按日历期对齐
经营现金流MLABPD
| Q4 25 | $18.8M | $24.8M | ||
| Q3 25 | $8.2M | $34.0M | ||
| Q2 25 | $1.9M | $30.7M | ||
| Q1 25 | $12.7M | $31.4M | ||
| Q4 24 | $18.1M | $22.1M | ||
| Q3 24 | $5.3M | $35.8M | ||
| Q2 24 | $10.7M | $28.6M | ||
| Q1 24 | $12.9M | $22.2M |
自由现金流MLABPD
| Q4 25 | $18.0M | $24.1M | ||
| Q3 25 | $7.1M | $33.1M | ||
| Q2 25 | $884.0K | $30.2M | ||
| Q1 25 | $11.9M | $30.3M | ||
| Q4 24 | $17.3M | $21.5M | ||
| Q3 24 | $3.5M | $35.1M | ||
| Q2 24 | $9.9M | $28.2M | ||
| Q1 24 | $12.3M | $21.2M |
自由现金流率MLABPD
| Q4 25 | 27.7% | 19.3% | ||
| Q3 25 | 11.7% | 26.8% | ||
| Q2 25 | 1.5% | 25.2% | ||
| Q1 25 | 19.2% | 24.9% | ||
| Q4 24 | 27.6% | 18.1% | ||
| Q3 24 | 6.0% | 30.3% | ||
| Q2 24 | 16.9% | 25.4% | ||
| Q1 24 | 21.0% | 19.1% |
资本支出强度MLABPD
| Q4 25 | 1.1% | 0.6% | ||
| Q3 25 | 1.8% | 0.7% | ||
| Q2 25 | 1.7% | 0.4% | ||
| Q1 25 | 1.2% | 0.9% | ||
| Q4 24 | 1.3% | 0.5% | ||
| Q3 24 | 3.1% | 0.5% | ||
| Q2 24 | 1.5% | 0.4% | ||
| Q1 24 | 0.9% | 0.9% |
现金转化率MLABPD
| Q4 25 | 5.17× | 0.15× | ||
| Q3 25 | 3.32× | 3.55× | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
